Healthcare M&A » By The Online Investor Staff, updated Sun., Apr. 11, 9:49 PM
Recent mergers and acquisitions in the Healthcare M&A category.
| This Slide: #88 of 100 |
Slide #88. Elanco, the animal health division of Eli Lilly and Company — Lohmann Animal Health
Acquirer:
Elanco, the animal health division of Eli Lilly and Company (NYSE:LLY)
Acquiree:
Lohmann Animal Health
Details:
Elanco, the animal health division of Eli Lilly and Company (NYSE:LLY), today announced an agreement to acquire Lohmann SE (Lohmann Animal Health), a privately-held company headquartered in Cuxhaven, Germany. Lohmann Animal Health is a global leader in the supply of poultry vaccines and also markets a range of feed additives. The acquisition will establish Elanco as a global poultry leader, solidify Elanco's vaccine presence, broaden Elanco's product offerings and significantly augment Elanco's vaccine manufacturing capabilities.
Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s products include: diabetes products, oncology products, immunology products, neuroscience products, and other therapies. Co.'s diabetes products include: Baqsimi®, Basaglar®, Humalog®, Humulin®, Jardiance®, Lyumjev®, Trajenta®, and Trulicity®. Co.'s oncology products include: Alimta®, Cyramza®, Erbitux®, Retevmo®, Tyvyt®, and Verzenio®. Co.'s immunology products include: Olumiant® and Taltz®. Co.'s neuroscience products include: Cymbalta®, Emgality®, Reyvow®, and Zyprexa®. Co.'s other therapies include: Bamlanivimab, Cialis®, and Forteo®.
Eli Lilly SEC Filing Email Alerts Service
Open the LLY Page at The Online Investor »
|
||||||||||||||||||||||||
Open the LLY Page at The Online Investor (in a new window) »
|
|
Avg. Broker Rec.
 
|
Strong Buy (3.50 out of 4) 56th percentile
(ranked higher than approx. 56% of all stocks covered)
Analysts' Target Price: LLY Stock Forecast Based on Zacks ABR data; powered by Xignite |
